AQR Capital Management
ACOR

AQR Capital Management’s Acorda Therapeutics ACOR Stock Holding History

AQR Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8,012
Closed -$706K – 2300
2020
Q2 		$706K Buy
8,012
+652
+9% +$68.9K ﹤0.01% 1617
2020
Q1 		$824K Sell
7,360
-4,067
-36% -$801K ﹤0.01% 1415
2019
Q4 		$2.8M Buy
11,427
+5,787
+103% +$1.46M ﹤0.01% 1141
2019
Q3 		$1.94M Buy
5,640
+3,666
+186% +$1.99M ﹤0.01% 1289
2019
Q2 		$1.82M Sell
1,974
-363
-16% -$446K ﹤0.01% 1297
2019
Q1 		$3.73M Buy
2,337
+951
+69% +$1.71M ﹤0.01% 1088
2018
Q4 		$2.59M Buy
1,386
+374
+37% +$814K ﹤0.01% 1151
2018
Q3 		$2.39M Buy
1,012
+823
+435% +$2.55M ﹤0.01% 1326
2018
Q2 		$650K Sell
189
-466
-71% -$1.43M ﹤0.01% 1895
2018
Q1 		$1.86M Sell
655
-2,601
-80% -$7.79M ﹤0.01% 1390
2017
Q4 		$8.38M Buy
3,256
+1,316
+68% +$3.74M 0.01% 837
2017
Q3 		$5.51M Buy
1,940
+56
+3% +$148K 0.01% 985
2017
Q2 		$4.45M Buy
1,884
+805
+75% +$1.59M 0.01% 1062
2017
Q1 		$2.72M Buy
1,079
+351
+48% +$1.01M ﹤0.01% 1250
2016
Q4 		$1.64M Buy
728
+68
+10% +$162K ﹤0.01% 1499
2016
Q3 		$1.65M Buy
660
+50
+8% +$149K ﹤0.01% 1503
2016
Q2 		$1.87M Buy
610
+223
+58% +$725K ﹤0.01% 1334
2016
Q1 		$1.23M Buy
+387
New +$1.61M ﹤0.01% 1497
2015
Q3 		– Sell
-444
Closed -$1.78M – 2284
2015
Q2 		$1.78M Sell
444
-416
-48% -$1.61M ﹤0.01% 1230
2015
Q1 		$3.44M Buy
860
+192
+29% +$879K 0.01% 913
2014
Q4 		$3.28M Buy
668
+262
+65% +$1.12M 0.01% 1071
2014
Q3 		$1.65M Sell
406
-88
-18% -$330K ﹤0.01% 1369
2014
Q2 		$2M Buy
494
+22
+5% +$89.7K 0.01% 1292
2014
Q1 		$2.15M Buy
472
+75
+19% +$303K 0.01% 1264
2013
Q4 		$1.39M Sell
397
-116
-23% -$452K ﹤0.01% 1567
2013
Q3 		$2.11M Buy
513
+262
+104% +$1.13M 0.01% 1254
2013
Q2 		$993K Buy
+251
New +$1.03M ﹤0.01% 1579

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AQR Capital Management's ACOR Position: Q3 2020 in Review

AQR Capital Management sold out of Acorda Therapeutics (ACOR) in Q3 2020, closing a stake of 8,012 shares — an estimated $706K sold.

AQR Capital Management first reported a position in ACOR in Q2 2013 and held it in 27 quarters. The position peaked at $8.38M in Q4 2017. 60 funds tracked by Wall St. Rank hold ACOR as of Q3 2020.

  • AQR Capital Management reported no remaining Acorda Therapeutics position as of Q3 2020 after selling out during the quarter.
  • AQR Capital Management sold 8,012 Acorda Therapeutics shares in Q3 2020, an estimated $706K.
  • AQR Capital Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 27 quarters.
  • AQR Capital Management's Acorda Therapeutics position peaked at $8.38M in Q4 2017.
  • 60 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2020.

Based on AQR Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.